Home > Inhibitors & Agonists > Others > Other Targets

Other Targets

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC23731 iMDK iMDK is a small molecule inhibitor of the growth factor Midkine (MDK) that suppresses the endogenous expression of MDK but not other growth factors such as PTN or VEGF.
DC8890 Imidafenacin Featured Imidafenacin(KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors with Kb of 0.317 nM; less potent for M2 receptors(IC50=4.13 nM).
DC20211 Imidazole;1,3-diazole; glyoxaline; 1,3-diazacyclopenta-2,4-diene Imidazole is a heterocyclic aromatic organic compound. It can be incorporated into many important biological molecules and acts as a corrosion inhibitor for industrial applications.
DC22092 Imidazole ketone erastin(IKE) Featured Imidazole ketone erastin (IKE, Ferroptosis inducer IKE) is a potent, metabolically stable inhibitor of system xc- and inducer of ferroptosis potentially suitable for in vivo applications.
DC20207 Imidazole-4(5)-acetic Acid Hydrochloride Imidazole-4(5)-acetic Acid Hydrochloride is a competitive antagonist at GABAC receptors.
DC21292 Imipenem Imipenem (MK-0787) is a broad-spectrum, semi-synthetic beta-lactam carbapenem that has broad antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains..
DC8988 Imiquimod Featured Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist and is commonly used topically to treat warts on the skin of the genital and anal areas.
DC10406 Imisopasem manganese Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.
DC21145 IMM-01 IMM-01 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 140 nM.
DC21146 IMM-02 IMM-02 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 99 nM.
DC10027 Importazole Featured Importazole is an inhibitor of importin-β transport receptors.
DC8874 7-TACA Impurity D of Cefoperazone
DC12578 IMTPPE Featured IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.
DC8450 (R)-Equol In contrast to the estrogen receptor (ER) selectivity of (S)-equol , (R)-equol is a weaker ER agonist that binds to ERα and ERβ with Ki values of 27.4 and 15.4 nM, respectively.
DC23397 INCB054329 INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.
DC20176 INCB057643 Featured INCB057643 is a BET inhibitor that binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones.
DC26025 INCB086550(INCB-086550) Featured INCB086550 is an orally available, small molecule inhibitor of PD-L1 with potential immune checkpoint inhibitory and antineoplastic activities. In vitro, INCB086550 selectively and potently blocked the PD-L1/PD-1 interaction, induced PD-L1 dimerization and internalization, and induced stimulation-dependent cytokine production in primary human immune cells. In vivo, INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade. Preliminary data from an ongoing phase I study confirmed PD-L1/PD-1 blockade in peripheral blood cells, with increased immune activation and tumor growth control.
DC21497 INCB10820 INCB10820 (PF-4178903) is a potent, selective, orally bioavailable dual CCR2 and CCR5 antagonist with binding IC50 of 3.0 nM and 5.3 nM, respectively.
DC11311 Incensole Incensole is a diterpene originally isolated from frankincense produced by B. carterii.It inhibits degradation of inhibitor of NF-κB (IκBα) in a concentration-dependent manner in TNF-α-stimulated HeLa cells when used at concentrations ranging from 60 to 1
DCAPI1136 Indapamide (Lozol) Indapamide (Lozol)
DC21246 Indimitecan Indimitecan (LMP776, NSC 725776) is an anticancer DNA Topoisomerase I (Top1) inhibitor..
DC8906 Indinavir Featured Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
DC8838 Indirubin Featured Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 μM and 0.6 μM.
DC20984 Indisulam Featured Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines.
DC23921 Indolactam V Indolactam V ((-)-Indolactam V) is an indole alkaloid tumor promoter that activates protein kinase C (PKC), binds to PKC regulatory domains of mouse skin PKCη and rat brain PKCγ with Ki values of 3.4 nM and 1 uM, respectively.
DCAPI1311 Indole-3-carbinol Featured Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
DCAPI1237 Indomethacin (Indocid, Indocin) Indomethacin (Indocid, Indocin)
DC9568 Indoprofen Indoprofen is a non-steroidal anti-inflammatory drug, provide insight into treatments for spinal muscular atrophies.
DC20276 Indotecan(LMP400) Featured Indotecan(LMP400) is a novel selective and potent topoisomerase I inhibitor with potential anticancer activitity.
DC21138 Inflachromene Featured Inflachromene (ICM) is a microglial inhibitor with anti-inflammatory effects, directly binds high mobility group protein 1 (HMGB1) and HMGB2 and reduces their cytoplasmic accumulation in microglial cells.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X